Caspase-3 Is Required for alpha -Fodrin Cleavage but Dispensable for Cleavage of Other Death Substrates in Apoptosis*

Reiner U. JänickeDagger , Patrick Ng, Michael L. Sprengart, and Alan G. Porter

From the Institute of Molecular and Cell Biology, The National University of Singapore, 30 Medical Dr., Singapore 117609, Republic of Singapore

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Although the commonly activated death protease caspase-3 appears not to be essential for apoptosis during development except in the brain, it was not shown whether substrates known to be cleaved by caspase-3 are still proteolyzed in its absence. We have addressed this question with MCF-7 breast carcinoma cells that we recently showed lack caspase-3 owing to the functional deletion of the CASP-3 gene. Tumor necrosis factor- or staurosporine-induced apoptosis of caspase-3-deficient MCF-7 cells resulted in cleavage of the death substrates PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45, but not alpha -fodrin. In contrast, all these substrates including alpha -fodrin were cleaved in apoptotic HeLa cells expressing caspase-3. Introduction of CASP-3 cDNA, but not CASP-10 cDNA, into MCF-7 cells restored alpha -fodrin cleavage. In addition, tumor necrosis factor- or staurosporine-induced apoptosis of MCF-7 cells stably expressing pro-caspase-3 also resulted in alpha -fodrin cleavage. Although the specific caspase inhibitory peptides Z-VAD-fmk and Z-DEVD-fmk prevented apoptosis of MCF-7 cells, we were unable to detect activation of caspases 2 and 7, which are known to be inhibited by Z-DEVD-fmk. Together our results suggest that caspase-3 is essential for cleavage of alpha -fodrin, but dispensable for the cleavage of PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45 and imply that one or more caspases other than caspases 2, 3, and 7 is activated and plays a crucial role in the cleavage of these substrates in MCF-7 cells.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Programmed cell death (apoptosis) is an essential mechanism for controlling cell numbers in metazoan organisms (1). Among the many known effectors and regulators of apoptosis, a distinct class of aspartyl proteases (ICE1-like proteases or caspases) stands out as being crucial for apoptosis in almost all cell types examined (2-4). Caspases are present as inactive zymogens containing an N-terminal prodomain and large and small catalytic subunits. They are activated either by autocatalytic processing and/or cleavage by other caspases at internal Asp residues following a variety of death stimuli including tumor necrosis factor (TNF), Fas ligand, staurosporine, or etoposide.

Ten distinct caspases have been identified that can be grouped into three subfamilies based on their substrate specificities (4-6). Group I caspases (caspases 1, 4, and 5) prefer the tetrapeptide sequence WEHD and are believed to play a role mainly in inflammation, whereas members of group II (caspases 2, 3, and 7) and group III (caspases 6, 8, 9, and 10) with the optimal peptide recognition motifs DExD and (I/L/V)ExD, respectively, are mainly involved in apoptosis (4-6). The fact that caspases 8 and 10 each contain two N-terminal located death effector domains (DED) that enable them to associate with death receptors, places these two caspases most upstream in the apoptotic activation pathway (7-9). In contrast, caspase-3 is believed to play the role of the executioner most downstream in the apoptotic pathways as it is commonly activated in cells by various death stimuli (10-13). Many different substrates are apparently cleaved by caspase-3, notably DNA fragmentation factor (DFF-45) (14), the actin regulatory protein gelsolin (15), the DNA repair enzymes poly(ADP-ribose) polymerase (PARP) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs), structural proteins such as alpha -fodrin (16, 17), the signaling enzymes protein kinase Cdelta (PKCdelta ), cytosolic phospholipase A2 (cPLA2), sterol-regulatory element-binding proteins, and p21-activated kinase 2 (PAK2) (4, 18-20). Although it seems likely that the selective cutting of these and other key proteins is detrimental to the cell, it is unclear which of the substrates must be cleaved to commit the cell to die and to ensure apoptosis. Elucidating the substrate specificities of the individual proteases in vivo is another largely unsolved problem and is complicated by the fact that most caspases cleave more than one caspase precursor and/or substrate in vitro (4, 19, 20).

Mice with a homozygous deletion in the CASP-3 gene show hyperplasia and abnormalities only in the brain, demonstrating that caspase-3 is essential for normal brain development (21). Furthermore, using the MCF-7 breast carcinoma cell line that lacks caspase-3 due to the functional deletion of the CASP-3 gene (22), we and others have recently demonstrated that caspase-3 is required for DNA fragmentation and blebbing (22) and for apoptosis induced by cytochrome c (23), but is not essential for TNF-, staurosporine- (22), or Fas-induced apoptosis (23). However, with the exception of PARP (21), it was not shown whether substrates known to be cleaved by caspase-3 are still proteolyzed in its absence, which other caspases are activated in apoptotic caspase-3-deficient cells, and whether various cleavage events are necessary for the cell to die. These questions are addressed in more detail in this paper.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell Lines, Reagents, and Antibodies-- All cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 10 mM glutamine, and 50 µg (each) of streptomycin and penicillin/ml (24). The human breast carcinoma cell line MCF-7 was obtained from the ATCC.

The caspase inhibitory peptides benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk) and Z-Asp-Glu-Val-Asp-fmk (Z-DEVD-fmk) were obtained from CLONTECH, and the protease inhibitors aprotinin, bacitracin, antipain, leupeptin, and phenylmethylsulfonyl fluoride as well as staurosporine were purchased from Sigma. TNF was recombinant human TNF-alpha with a specific activity of 4 × 107 units/mg of protein. Purified, active recombinant human caspases 3, 6, 7, and 8 were purchased from Pharmingen. The following antibodies were used: monoclonal antibodies to gelsolin were from Sigma. The monoclonal antibodies to CPP32 (caspase-3), Ich-1L (caspase-2), and gelsolin were purchased from Transduction Laboratories Inc. The polyclonal antibodies raised against ICE (caspase-1), TX (caspase-4), Mch4 (caspase-10), Mch5 (caspase-8), DNA-PKcs, and PAK2, as well as the monoclonal antibodies to Rb (Rb-IF8) were bought from Santa Cruz Biotechnology. Polyclonal caspase-7 and caspase-9 antibodies were generated by immunizing rabbits with the synthetic peptides KPDRSSFVPSLFSKKKKN and MDEADRRLLRR corresponding to the N terminus of the putative p20 subunit of caspase-7 and to the N terminus of the prodomain of caspase-9, respectively (25, 26). The monoclonal anti-non-erythroid spectrin (alpha -fodrin; mAb1622) antibodies were from Chemicon International Inc., and the monoclonal anti-PARP antibodies were obtained from G. G. Poirier. The polyclonal antibodies raised against DFF-45 were from X. Wang.

Preparation of Nuclear Extracts, Cell Extracts, and Western Blotting-- Nuclear and cell extracts were prepared as described (24, 27) in the presence of 1 mM phenylmethylsulfonyl fluoride and 10 µg/ml each of aprotinin, bacitracin, antipain, and leupeptin. To confirm equal loadings, protein concentrations were determined with the Bio-Rad protein assay. For detection of Rb, PARP, DNA-PKcs, and alpha -fodrin cleavage, nuclear extracts and cell extracts were separated in 0.1% SDS, 6.5% polyacrylamide gels and subjected to Western blotting as described (27). The cell extracts for the detection of PAK2, gelsolin, DFF-45, and the various caspases were fractionated in 0.1% SDS, 12.5% polyacrylamide gels. The proteins were visualized by the Amersham Pharmacia Biotech ECL kit.

cDNAs and Transfection of MCF-7 Cells-- The plasmid pcDNA3 containing the full-length Yama (CASP-3) cDNA was provided by V. Dixit. The cDNA encoding the full-length Mch4 (CASP-10) cDNA (7) was obtained by polymerase chain reaction and cloned into the expression vector pcDNA3 (Invitrogen). For the microscopic assessment of apoptotic cell death, 1 × 105 MCF-7 cells per well of a 24-well plate were transiently transfected using the SuperFect Reagent (Qiagen) with 0.3 µg of pCMV-beta -galactosidase in the presence of 0.9 µg of pcDNA3 containing full-length cDNA of CASP-3 or CASP-10. At 40 h post-transfection, cells were fixed and stained for beta -galactosidase expression as described (28). Transfection efficiency was approximately 40-60%. For Western blot analysis of death substrates, 5 × 105 MCF-7 cells in a 60-mm dish were transiently transfected with 5 µg of plasmids (without the pCMV-beta -galactosidase construct). At 40 h post-transfection, nuclear extracts and cell extracts were prepared and analyzed as described above. MCF-7 cells were stably transfected with the CASP-3 cDNA as described (22).

Measurement of Cell Death, DEVD-pNA Cleavage Activity, and in Vitro Cleavage of Rb-- To induce apoptosis, cells were either treated with a combination of TNF (30 ng/ml) and cycloheximide (Chx; 10 µg/ml) (Sigma) or staurosporine (1 µM). Cell death was either assessed by microscopic examination, trypan blue uptake or was measured with the standard TNF cytotoxicity assay as described previously (24). The DEVD activity assay which is based on the spectrophotometric detection of the chromophore paranitroanilide (pNA) after cleavage from the labeled substrate DEVD-pNA by caspase-3 (or a caspase-3-like) protease was performed with the ApoAlertTM CPP32 Colorimetric Assay Kit (CLONTECH) according to the protocol of the manufacturer. For the protease cleavage assays, Rb was synthesized in the presence of [35S]methionine as described (29). Cleavage reactions were performed for 2 h at 37 °C using 3 µl of in vitro translated Rb and 200 ng of active caspases in 30 µl containing 20 mM PIPES (pH 7.2), 100 mM NaCl, 10 mM dithiothreitol, 1 mM EDTA, 0.1% CHAPS, and 10% sucrose, and analyzed in 0.1% SDS-6.5% polyacrylamide gels followed by autoradiography.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Only Caspase-8 Is Activated in TNF-treated, but Not in Staurosporine-treated MCF-7 Cells-- We have recently demonstrated that the human MCF-7 breast carcinoma cell line is devoid of caspase-3 owing to the functional deletion of the CASP-3 gene (22). Despite the lack of caspase-3, MCF-7 cells are still sensitive to a variety of apoptosis inducers such as transforming growth factor-beta 1 (30), Fas (23), and TNF or staurosporine (22) indicating that other caspases may be activated.

To examine whether MCF-7 cells specifically lack only pro-caspase-3 and to determine which pro-caspases are activated in TNF/Chx- or staurosporine-induced apoptosis, control and apoptotic cell lysates of MCF-7 cells were probed with antibodies to various caspases. As a control, lysates of similarly treated HeLa D98 and H21 cells which are highly or only marginally sensitive to TNF, respectively (24), were included. Besides caspase-3, MCF-7 cells also lack detectable levels of pro-caspase-1 which, however, is present in both HeLa cell lines (Fig. 1). All other pro-caspases tested (pro-caspases 2, 5, 7, 8, 9, and 10) were present in all three cell lines examined (Fig. 1). There was some variation in the protein levels of pro-caspases 2 and 7 in HeLa and MCF-7 cells, but pro-caspases 5, 9, and 10 were equally expressed in all three cell types (Fig. 1).


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   Caspase-8, but none of the other tested caspases, is activated in apoptotic MCF-7 cells. Western blot analysis of the expression of the indicated pro-caspases (or caspase-8 fragments) in lysates of untreated HeLa D98, HeLa H21, or MCF-7 cells (lanes 1, 4, and 7), HeLa cells treated for 4 h (lanes 2 and 5) or MCF-7 cells treated for 20 h (lane 8) with TNF/Chx, and cells treated for 16 h with staurosporine (lanes 3, 6, and 9).

In addition to the observed activation of caspase-3 in HeLa D98 and HeLa H21 cells following a death stimulus (Fig. 1), only caspase-8, but none of the other caspases, was activated by both death stimuli to various degrees as demonstrated by the appearance of a singlet band or doublet of approximately 24-26 kDa (Fig. 1, lanes 2, 3, 5, 6, and 8). These proteins which were present only in apoptotic lysates most likely represent intermediate cleavage products of caspase-8, as demonstrated previously in vitro and in vivo (31). Interestingly, in all three cell lines examined, caspase-8 was efficiently and similarly activated by TNF/Chx (Fig. 1, lanes 2, 5, and 8), despite the fact that only 18% of the HeLa H21 cells were killed by this death stimulus (Fig. 1). In contrast, all three cell lines were killed to a similar extent following a 16-h staurosporine treatment (Fig. 1), which, however, resulted only in a marginal and almost undetectable activation of caspase-8 in HeLa H21 and in MCF-7 cells, respectively (Fig. 1, lanes 6 and 9). These data are in agreement with reports demonstrating an important role for caspase-8 predominantly in TNF- or Fas-mediated apoptosis (8, 9, 31), but also suggest that caspase-8 (like caspase-3) may not always be essential for apoptosis, even though both caspases are commonly activated by a variety of death stimuli (10, 13, 31, 32).

Cleavage of Death Substrates but Not of alpha -Fodrin in Caspase-3-deficient MCF-7 Cells-- Having established that MCF-7 cells lack pro-caspases 1 and 3, but express other apoptosis-related pro-caspases, we examined control and apoptotic cell lysates of HeLa D98, HeLa H21, and MCF-7 cells for the status of various death substrates known to be cleaved by caspase-3 or a caspase-3-like protease (4, 19). The same experimental conditions were applied as described in Fig. 1. The cleavages of PARP, the retinoblastoma protein (Rb), alpha -fodrin, and DNA-PKcs could be readily assessed by the appearance of the corresponding fragments in apoptotic lysates, whereas proteolysis of PAK2, gelsolin, and DFF-45 was judged by the decrease in the intensity of the full-length proteins. Two different antibodies to PAK2 and gelsolin both gave the same results, but no fragments were detected. Nevertheless, with the exception of alpha -fodrin, all substrates tested including PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45 were still cleaved in caspase-1- and caspase-3-deficient MCF-7 cells (Fig. 2, lanes 8 and 9). Except for gelsolin which was only cleaved in staurosporine-treated, but not in TNF/Chx-treated, MCF-7 cells (a pattern also observed in D98 cells; Fig. 2, lanes 2 and 3), all substrates were cleaved to a similar extent in MCF-7 cells treated with TNF/Chx or staurosporine (Fig. 2, lanes 8 and 9). This is in contrast with the cleavage patterns obtained in the two HeLa cell lines, in which most of the substrates were cleaved more efficiently in TNF/Chx-treated cells (Fig. 2, lanes 1-6). Together with our results demonstrating that of all the caspases tested only caspase-8 was activated in MCF-7 cells by TNF/Chx but not by staurosporine (Fig. 1), these data provide evidence for the existence of other as yet unknown caspases that cleave PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 2.   alpha -Fodrin is not cleaved in apoptotic MCF-7 cells. Western blot analysis of the expression of the indicated death substrates in nuclear extracts (PARP, Rb, and DNA-PKcs) or in cell lysates (alpha -fodrin, PAK2, gelsolin, and DFF-45) of untreated HeLa D98, HeLa H21, or MCF-7 cells (lanes 1, 4, and 7), HeLa cells treated for 4 h (lanes 2 and 5), or MCF-7 cells treated for 20 h (lane 8) with TNF/Chx, and cells treated for 16 h with staurosporine (lanes 3, 6, and 9).

Interestingly, alpha -fodrin, known to be cleaved by caspase-3 but not by caspases 1 and 2 (16, 17), was the only substrate tested that was resistant to caspase cleavage in apoptotic lysates of TNF/Chx- or staurosporine-treated MCF-7 cells, based on the absence of the typical 120-kDa fragment (Fig. 2, lanes 8 and 9). Although both death stimuli induced the formation of a 150-kDa alpha -fodrin fragment in all three cell lines including MCF-7 cells (Fig. 2, lanes 2, 3, 5, 6, 8, and 9), this fragment was recently shown to be the product of the thiol protease calpain, an enzyme unrelated to caspases (33). Taken together, these results imply that of all the substrates tested, only cleavage of alpha -fodrin appears to require the activation of caspase-3.

Caspase-3 Induces Apoptosis in MCF-7 Cells, and alpha -Fodrin and PARP, but Not Rb, Are Cleaved-- To assess whether certain cleavage events are necessary for apoptosis, MCF-7 cells were transiently transfected with a pSV-beta -galactosidase plasmid in the presence of a 3-fold excess of vector alone or an expression construct encoding full-length pro-caspase-3. As a further control, an expression construct encoding pro-caspase-10 was also introduced into MCF-7 cells. Almost all CASP-10-transfected MCF-7 cells were dead (95%) in contrast to only 50-60% of MCF-7 cells transfected with the CASP-3 cDNA (Fig. 3A). This difference can be most likely explained by the facts that caspase-10 is a more upstream protease that is capable of activating other caspases (7) and that caspase-3 may not be able to autocatalyze as efficiently, which is supported by the presence of some inactive caspase-3 precursor remaining in CASP-3-transfected MCF-7 cells (Fig. 3B, upper panel, lane 4). Regardless of the explanation, these results indicate that caspase-3 can activate a death pathway in MCF-7 cells. More importantly, Western blot analysis showed that the overexpression of pro-caspase-3 (but not pro-caspase-10) led to the cleavage of alpha -fodrin giving rise to the typical 120-kDa fragment (Fig. 3B, compare lanes 4 and 5). Surprisingly, Rb was not cleaved in the presence of caspase-3 (Fig. 3B, lane 4), although the cleavage site in Rb (DEADdown-arrow G) appears to be close to a typical caspase-3 recognition motif (29, 34). Likewise, little or no Rb cleavage was observed in MCF-7 cells transfected with CASP-10 (Fig. 3B, lane 5). PARP, on the other hand, was cleaved into the signature 85-kDa apoptotic fragment in MCF-7 cells transfected with either the CASP-3 or CASP-10 cDNAs (Fig. 3B, lanes 4 and 5).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 3.   Transient transfection of pro-CASP-3 or pro-CASP-10 cDNAs results in apoptosis of MCF-7 cells and in cleavage of specific death substrates. A, induction of apoptosis by caspases 3 and 10. MCF-7 cells were transiently transfected in the presence of a pCMV-beta -galactosidase construct with expression vector pcDNA3 encoding full-length pro-CASP-3, pro-CASP-10, or with vector alone. The cells were fixed and stained for beta -galactosidase expression 40 h following transfection. The data shown (means ± S.D., n = 4) are the percentage of apoptotic round blue cells. B, substrate specificity of caspases 3 and 10. MCF-7 cells were transiently transfected with the expression vectors described above (without the pCMV-beta -galactosidase construct), and cell lysates (for the expression of pro-caspase-3 and alpha -fodrin) or nuclear extracts (for the expression of PARP and Rb) were prepared 40 h after transfection. Western blot analysis of the expression of the indicated death substrates was performed with lysates of MCF-7 cells transfected with vector alone (lane 3), CASP-3 (lane 4), or CASP-10 (lane 5). As controls for the cleavages, nuclear extracts (PARP and Rb) or cell lysates (caspase-3 and alpha -fodrin) from untransfected MCF-7 cells either untreated (lane 1) or treated for 20 h with TNF/Chx (lane 2) were included.

To further investigate whether caspase-3 is required for alpha -fodrin cleavage, MCF-7 cells stably expressing pro-caspase-3 (22) were treated with TNF/Chx or staurosporine, and alpha -fodrin cleavage was monitored by Western blotting. Both death stimuli resulted in the activation of caspase-3 in three individual MCF-7 clones stably expressing pro-caspase-3 (Fig. 4, upper panels). Consistent with the caspase-3 activation profile obtained in apoptotic HeLa cells (Fig. 1), TNF/Chx treatment of the three pro-caspase-3-expressing MCF-7 clones resulted in a more efficient activation of this protease than the treatment with staurosporine (Fig. 4, upper panels). More importantly, processing of pro-caspase-3 in these cells was accompanied by the cleavage of alpha -fodrin into the typical 120-kDa fragment (Fig. 4, lower panels). Similar to the results obtained with parental caspase-3-deficient MCF-7 cells (Figs. 2 and 3B), TNF/Chx or staurosporine treatment of vector-transfected MCF-7 cells did not result in the appearance of the 120-kDa alpha -fodrin fragment (Fig. 4, lower panel, lanes 1-3). Taken together, these results clearly demonstrate that cleavage of alpha -fodrin requires caspase-3 activity.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 4.   TNF treatment of MCF-7 cells stably expressing CASP-3 cDNA results in alpha -fodrin cleavage. Western blot analysis of the presence of pro-caspase-3 (upper panels) and alpha -fodrin (lower panels) in lysates of three individual MCF-7 clones stably expressing CASP-3 (MCF-7.3.6, lanes 4-6; MCF-7.3.25, lanes 7-9; MCF-7.3.28, lanes 10-12) and MCF-7 cells transfected with the vector alone (MCF-7.0.19, lanes 1-3). Cells were either untreated (lanes 1, 4, 7, and 10) or were treated for 16 h with TNF/Chx (lanes 2, 5, 8, and 11) or for 16 h with staurosporine (lanes 3, 6, 9, and 12).

Rb Is Cleaved in Vitro by Caspase-7-- To investigate which caspase is responsible for Rb cleavage, the non-phosphorylated form of Rb was synthesized in vitro in the presence of [35S]methionine and incubated with various recombinant active caspases. In agreement with our result that induction of apoptosis by transient expression of pro-caspase-3 does not result in the cleavage of Rb (Fig. 3B), this experiment revealed that only caspase-7, but not caspases 3, 6, or 8, cleaved Rb (Fig. 5). The observed cleavage pattern of Rb by caspase-7 was similar to that obtained in vivo and in vitro in nuclear extracts of apoptotic cells (29), suggesting that caspase-7 or a closely related protease may be responsible for cleavage of Rb in vivo.


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 5.   Caspase-7 cleaves Rb in vitro. In vitro translated [35S]methionine-labeled Rb (29) was incubated for 2 h at 37 °C in the absence (lane 1) or presence of the indicated caspases (lanes 2-5). Proteins were fractionated by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography.

Lack of DEVD Activity in Caspase-3-deficient MCF-7 Cells-- Based on their substrate specificities, caspase-3 together with caspases 2 and 7 belongs to the group II subfamily of caspases that preferentially cleave the peptide sequence DExD found in many death substrates (4-6). These caspases are believed to be the final executioners whereas (except for caspase-6) caspases of group III (caspases 6, 8, 9, and 10) with an optimal recognition sequence (I/L/V)ExD appear to play a more apical role in apoptosis. Of all the caspases tested, only caspase-8 was activated by TNF/Chx in caspase-3-deficient MCF-7 cells (Fig. 1, lane 8). However, with the exception of alpha -fodrin, substrates known to be cleaved by caspase-3 or caspase-3-like proteases (PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45) were still proteolyzed in apoptotic MCF-7 cells (Fig. 2), suggesting that other DEVD-specific caspases cleave these substrates. To examine this possibility, we assayed lysates of untreated and TNF/Chx- or staurosporine-treated HeLa D98, HeLa H21, and MCF-7 cells for DEVD activity, which is based on the specific cleavage of the substrate DEVD-paranitroanilide (DEVD-pNA) by caspase-3 (or a caspase-3-like protease). Surprisingly, MCF-7 cells lack any detectable DEVD-pNA-cleaving activity following treatment with TNF/Chx or staurosporine, whereas both death stimuli induced substantial DEVD-pNA-cleaving activity in HeLa D98 and H21 cells, with TNF/Chx being the most potent inducer (Fig. 6).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 6.   Detectable DEVD-pNA-cleaving activity in apoptotic HeLa D98 and H21 cells but not in MCF-7 cells. Lysates of untreated (control) cells or cells treated for 4 h (D98) or 20 h (H21 and MCF-7) with TNF/Chx or for 20 h (all cells) with staurosporine were assayed for DEVD activity as described under "Experimental Procedures." The values are derived from one representative experiment of four performed in duplicates.

Specific Caspase Inhibitors Prevent Apoptosis in MCF-7 Cells-- Next we investigated the apparent paradox that substrates known to be cleaved by DEVD-specific caspases are still proteolyzed in MCF-7 cells, which lack detectable DEVD-pNA-cleaving activity. For this purpose, MCF-7 cells and HeLa D98 cells were incubated with TNF/Chx or staurosporine in the absence or presence of cell-permeable, irreversible caspase inhibitory peptides (35). Z-VAD-fmk, a caspase inhibitor of broad specificity, completely prevented TNF-induced apoptosis of MCF-7 and HeLa D98 cells (Fig. 7). In addition, Z-DEVD-fmk, a selective inhibitor of the caspase-3 subfamily also inhibited TNF-induced apoptosis of both cell lines, although the protection was not surprisingly less efficient than that obtained with Z-VAD-fmk (Fig. 7). In contrast, both peptides were less efficient in protecting the two cell lines from staurosporine-induced apoptosis (Fig. 7). Interestingly, both Z-VAD-fmk and Z-DEVD-fmk protected HeLa D98 cells from TNF- or staurosporine-induced apoptosis in a dose-dependent fashion with maximum protection obtained in the 22-66 µM range, whereas in MCF-7 cells even the lowest concentration (7 µM) of either peptide resulted in the maximum protection against both death stimuli (Fig. 7). Taken together, these results show that TNF- or staurosporine-induced apoptosis of MCF-7 cells was inhibited by both peptides, indicating that DEVD-specific caspases are activated and can account for the observed substrate cleavages in these cells (Fig. 2).


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibition of apoptosis of HeLa D98 and MCF-7 cells by Z-VAD-fmk and Z-DEVD-fmk. HeLa D98 cells and MCF-7 cells were treated for 4 h or 20 h, respectively, with TNF/Chx (T/C) or for 20 h with staurosporine in the absence (control) or presence of various indicated concentrations of Z-VAD-fmk or Z-DEVD-fmk. Apoptosis was measured as described above. The values are derived from one representative experiment of three performed in triplicate.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In mice it was inferred that caspase-3 is not required for developmentally regulated apoptosis in tissues and organs other than the brain, but except for PARP cleavage in thymocytes, it was not shown whether other death substrates known to be cleaved by caspase-3 are still proteolyzed in its absence (21). We addressed this question with the MCF-7 cell line which readily undergoes apoptosis following treatment with various death stimuli (22, 23, 30) despite the functional deletion of the CASP-3 gene (22). alpha -Fodrin was the only substrate tested not to be cleaved into the 120-kDa fragment in caspase-3-deficient apoptotic MCF-7 cells, confirming that generation of this fragment is not required for apoptosis induced by TNF (17) or staurosporine. In these cells, alpha -fodrin was only cleaved into the 150-kDa fragment (most likely by calpain; Ref. 33), showing that proteolysis by a caspase and calpain are independent events. Introduction of the CASP-3 (but not CASP-10) gene into MCF-7 cells resulted in the cleavage of alpha -fodrin into the typical 120-kDa fragment. As it was recently shown in vitro that cleavage of this substrate was mediated by caspase-3 but not by caspases 1 or 2 (17), we conclude that the presence and activation of caspase-3 is required for cleavage of alpha -fodrin in vivo. Whether caspase-3 cleaves alpha -fodrin directly or via the activation of another caspase is presently unknown.

Remarkably, all other substrates tested including PARP, Rb, DNA-PKcs, PAK2, gelsolin, and DFF-45 were still cleaved in caspase-3-deficient apoptotic MCF-7 cells. Considering the fact that MCF-7 cells die without blebbing and DNA fragmentation (22, 30), these results were surprising as the reported caspase-3-mediated cleavages of gelsolin and PAK2 were implicated in the morphological changes associated with apoptosis (15, 18), and the cleavage of DFF-45 and its recently discovered mouse homolog ICAD by caspase-3 were shown to be important events in the initiation of DNA fragmentation (14, 36, 37). As introduction of the CASP-3 gene into MCF-7 cells resulted in DNA fragmentation and blebbing following TNF treatment (22), our present results indicate that besides the cleavages of PAK2, gelsolin, and DFF-45, additional caspase-3-dependent cleavage events are necessary for these processes to occur at least in MCF-7 cells. The cleavage of alpha -fodrin could contribute to the morphological changes, because fodrin is a major component of the cortical cytoskeleton of most eukaryotic cells (38), it has binding sites for actin, calmodulin, and microtubules (39), and its proteolysis has been recently suggested to contribute to the structural rearrangements including blebbing during apoptosis (16, 17). Our data presented here and in a previous study (22) strongly support this hypothesis, although additional studies with a non-cleavable alpha -fodrin protein are necessary to clarify this issue.

We have also shown that of all the caspases tested (caspases 1, 2, 3, 5, 7, 8, 9, and 10), only caspases 3 and 8 were detectably activated in TNF- or staurosporine-treated HeLa cells, and only caspase-8 was activated in TNF-treated MCF-7 cells. The available antibodies to caspases 4 and 6 were not of a sufficiently high quality for us to determine whether or not these caspases were present and activated. However, caspase-4 is believed to play a role in inflammation, and there is no evidence that it is involved in apoptosis (3, 40). Caspase-6, on the other hand, appears to cleave only the nuclear lamins during apoptosis (41-43). Moreover, the cleavage site specificities of caspases 4 and 6 (5, 6) suggest that they play no role in the cleavage of the substrates studied here. Likewise, the specificity and cellular localization of caspase-8 (5-8) argues against it directly cleaving Rb, DNA-PKcs, PAK2, gelsolin, and DFF-45. Furthermore, the degree of activation of caspases 3 and 8 often did not correlate with the amount of cell death and the extent of cleavage of the studied death substrates. This was strikingly illustrated in several ways. Firstly, these substrates were still cleaved in caspase-3-deficient MCF-7 cells in which none of the tested caspases (including caspase-8) were activated by staurosporine. Secondly, HeLa H21 cells were only marginally sensitive to TNF/Chx and highly sensitive to staurosporine, yet caspase-3 and -8 activation as well as cleavage of several death substrates were all far more pronounced in these cells treated with TNF/Chx than with staurosporine.

These observations raise the question: which caspases are required for apoptosis and cleavage of PARP, Rb, DNA-PKcs, PAK2, gelsolin, and DFF-45 in MCF-7 cells? Except for PARP which can be cleaved by various caspases (2-4), there is evidence from earlier work that these substrates are cleaved by caspase-3 or a caspase-3-like protease with a specificity for (P4)-DEVD-(P1) or a closely related sequence with an aspartic acid in the P4 position (14, 15, 18, 29, 34, 44, 45). The other known proteases with a specificity for DEVD (or a closely related sequence) are caspases 2 and 7. Interestingly, caspase-7 is far more abundant in MCF-7 cells than in the two HeLa cell lines. Together with our finding that caspase-7 cleaves Rb in vitro, as well as DFF-45,2 these observations raise the possibility that caspase-7 and/or caspase-2 compensate for the lack of caspase-3 in MCF-7 cells. However, our observation that caspases 2 and 7 were not detectably activated in these cells by TNF/Chx or staurosporine argues against the involvement of both caspases in the cleavage of these or any other substrates in MCF-7 cells. Serine proteases including calpain have been implicated in apoptosis (33, 46, 47); however the fact that the cleavages of PARP, Rb, DNA-PKcs, PAK2, gelsolin, and DFF-45 can be blocked by specific caspase inhibitory peptides (4, 14, 15, 18-20, 29) makes it unlikely that serine proteases play a crucial role in the cleavage of these substrates.

We have shown that TNF-induced apoptosis of HeLa D98 and MCF-7 cells was completely prevented by Z-VAD-fmk, a caspase inhibitory peptide of broad specificity, and to a lesser degree by Z-DEVD-fmk, which preferentially blocks the activity of caspases 2, 3, and 7 (4-6). These results indicate that in both cell lines the activation of caspases (including DEVD-specific caspases) is crucial in TNF-induced apoptosis, in agreement with the role of these caspases in Fas-mediated apoptosis (35). Surprisingly, and in contrast to HeLa D98 cells, no DEVD-pNA-cleaving activity was detectable in MCF-7 cells. The reason for this apparent discrepancy is unknown, but is does sound a cautionary note that failure to detect cleavage of the fluorescent substrate DEVD-pNA should not always be interpreted to mean that dying cells lack active DEVD-inhibitable caspases. Together with earlier studies showing that PARP, Rb, DNA-PKcs, PAK2, gelsolin, and DFF-45 are cleaved by a caspase-3-like protease (4, 14, 15, 18-20, 29), our results suggest that one or more caspase-3-like proteases other than caspases 2, 3, and 7 is crucial for specific cleavage of these substrates in apoptotic MCF-7 cells.

Transfection of CASP-3 or CASP-10 cDNAs into MCF-7 cells led to PARP cleavage and cell death, but Rb was not cleaved, from which two main conclusions can be drawn. First, caspases 3 and 10 are not involved in Rb cleavage, and, furthermore, the in vitro cleavage assays with purified active caspases showed that Rb is not a substrate for caspase-3. Second, Rb cleavage is not required for apoptosis mediated by CASP-3 or CASP-10 transfection, which is in sharp contrast to TNF- or Fas-induced apoptosis (29, 34). On the other hand, PARP is always cleaved by a caspase regardless of the death stimulus or cell type. PARP cleavage is believed to attenuate its ability to carry out DNA repair and so to hasten apoptosis (3, 4, 19). This is consistent with recent although still controversial findings that PARP is a survival factor and can counteract cell death (48) and confirms its status as a universal marker of apoptosis, which is in contrast to other substrates we tested.

    ACKNOWLEDGEMENTS

We gratefully acknowledge the generous gift of DFF-45 antibodies from X. Wang and the CASP-3 expression vector from V. Dixit.

    FOOTNOTES

* This work was funded by the Institute of Molecular and Cell Biology, National University of Singapore.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 65-874-3379; Fax: 65-779-1117; E-mail: mcbrj{at}imcb.nus.edu.sg.

1 The abbreviations used are: ICE, interleukin 1beta -converting enzyme; TNF, tumor necrosis factor; DED, death effector domains; PARP, poly(ADP-ribose) polymerase; DNA-PKcs, DNA-dependent protein kinase catalytic subunit; PKC, protein kinase C; Chx, cycloheximide; PIPES, 1,4-piperazinediethanesulfonic acid; CHAPS, 1,4-piperazinediethanesulfonic acid; pNA, p-nitroanilide; Rb, retinoblastoma protein.

2 X. Wang, personal communication.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Jacobson, M. D., Weil, M., and Raff, M. C. (1997) Cell 88, 347-354[Medline] [Order article via Infotrieve]
  2. Nicholson, D. W. (1996) Nature Biotechnol. 14, 297-301[Medline] [Order article via Infotrieve]
  3. Kumar, S., and Lavin, M. F. (1996) Cell Death Differ. 3, 255-267
  4. Nicholson, D. W., and Thornberry, N. A. (1997) Trends Biochem. Sci. 22, 299-306[CrossRef][Medline] [Order article via Infotrieve]
  5. Talanian, R. V., Quinlan, C., Trautz, S., Hackett, M. C., Mankovich, J. A., Banach, D., Ghayur, T., Brady, K. D., and Wong, W. W. (1997) J. Biol. Chem. 272, 9677-9682[Abstract/Free Full Text]
  6. Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. (1997) J. Biol. Chem. 272, 17907-17911[Abstract/Free Full Text]
  7. Fernandes-Alnemri, T., Armstrong, R. C., Krebs, J., Srinivasula, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7464-7469[Abstract/Free Full Text]
  8. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815[Medline] [Order article via Infotrieve]
  9. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827[Medline] [Order article via Infotrieve]
  10. Faleiro, L., Kobayashi, R., Fearnhead, H., and Lazebnik, Y. (1997) EMBO J. 16, 2271-2281[Abstract/Free Full Text]
  11. MacFarlane, M., Cain, K., Sun, X.-M., Alnemri, E. S., and Cohen, G. M. (1997) J. Cell Biol. 137, 469-479[Abstract/Free Full Text]
  12. Martins, L. M., Kottke, T., Mesner, P. W., Basi, G. S., Sinha, S., Frigon, N., Jr., Tatar, E., Tung, J. S., Bryant, K., Takahashi, A., Svingen, P. A., Madden, B. J., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. (1997) J. Biol. Chem. 272, 7421-7430[Abstract/Free Full Text]
  13. Takahashi, A., Hirata, H., Yonehara, S., Imai, Y., Lee, K.-K., Moyer, R. W., Turner, P. C., Mesner, P. W., Okazaki, T., Sawai, H., Kishi, S., Yamamoto, K., Okuma, M., and Sasada, M. (1997) Oncogene 14, 2741-2752[CrossRef][Medline] [Order article via Infotrieve]
  14. Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997) Cell 89, 175-184[Medline] [Order article via Infotrieve]
  15. Kothakota, S., Azuma, T., Reinhard, C., Klippel, A., Tang, J., Chu, K., McGarry, T. J., Kirschner, M. W., Koths, K., Kwiatkowski, D. J., and Williams, L. T. (1997) Science 278, 294-298[Abstract/Free Full Text]
  16. Martin, S. J., O'Brien, G. A., Nishioka, W. K., McGahon, A. J., Mahboubi, A., Saido, T. C., and Green, D. R. (1995) J. Biol. Chem. 270, 6425-6428[Abstract/Free Full Text]
  17. Cryns, V. L., Bergeron, L., Zhu, H., Li, H., and Yuan, J. (1996) J. Biol. Chem. 271, 31277-31282[Abstract/Free Full Text]
  18. Rudel, T., and Bokoch, G. (1997) Science 276, 1571-1574[Abstract/Free Full Text]
  19. Porter, A. G., Ng, P., and Jänicke, R. U. (1997) BioEssays 19, 501-507[Medline] [Order article via Infotrieve]
  20. Villa, P., Kaufmann, S. H., and Earnshaw, W. C. (1997) Trends Biochem Sci. 22, 388-393[CrossRef][Medline] [Order article via Infotrieve]
  21. Kuida, K., Zheng, T. S., Na, S., Kuan, C-Y., Yang, D., Karasuyama, H., Rakic, P., and Flavell, R. A. (1996) Nature 384, 368-372[CrossRef][Medline] [Order article via Infotrieve]
  22. Jänicke, R. U., Sprengart, M. L, Wati, M. R., and Porter, A. G. (1998) J. Biol. Chem. 273, 9357-9360[Abstract/Free Full Text]
  23. Li, F., Srinivasan, A., Wang, Y., Armstrong, R. C., Tomaselli, K. J., and Fritz, L. C. (1997) J. Biol. Chem. 272, 30299-30305[Abstract/Free Full Text]
  24. Jänicke, R. U., Lee, F. H. H., and Porter, A. G. (1994) Mol. Cell. Biol. 14, 5661-5670[Abstract]
  25. Duan, H., Chinnaiyan, A. M., Hudson, P. L., Wing, J. P., He, W.-W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 1621-1625[Abstract/Free Full Text]
  26. Duan, H., Orth, K., Chinnaiyan, A. M., Poirier, G. G., Froelich, C. J., He, W.-W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 16720-16724[Abstract/Free Full Text]
  27. Jänicke, R. U., Lin, X. Y., Lee, F. H. H., and Porter, A. G. (1996) Mol. Cell. Biol. 16, 5245-5253[Abstract]
  28. Kumar, S., Kinoshita, M., Noda, M., Copeland, N. G., and Jenkins, N. A. (1994) Genes Dev. 8, 1613-1626[Abstract]
  29. Jänicke, R. U., Walker, P. A., Lin, X. Y., and Porter, A. G. (1996) EMBO J. 15, 6969-6978[Abstract]
  30. Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E., Walker, P. R., and Sikorska, M. (1993) EMBO J. 12, 3679-3684[Abstract]
  31. Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P. H., and Peter, M. E. (1997) EMBO J. 16, 2794-2804[Abstract/Free Full Text]
  32. Chinnaiyan, A. M., Orth, K., O'Rourke, K., Duan, H., Poirier, G. G., and Dixit, V. M. (1996) J. Biol. Chem. 271, 4573-4576[Abstract/Free Full Text]
  33. Nath, R., Raser, K. J., Stafford, D., Hajimohammadreza, I., Posner, A., Allen, H., Talanian, R. V., Yuen, P., Gilbertsen, R. B., and Wang, K. W. (1996) Biochem. J. 319, 683-690[Medline] [Order article via Infotrieve]
  34. Tan, X., Martin, S. J., Green, D. R., and Wang, J. Y. J. (1997) J. Biol. Chem. 272, 9613-9616[Abstract/Free Full Text]
  35. Longthorne, V. L., and Williams, G. T. (1997) EMBO J. 16, 3805-3812[Abstract/Free Full Text]
  36. Sakahira, H., Enari, M., and Nagata, S. (1998) Nature 391, 96-99[CrossRef][Medline] [Order article via Infotrieve]
  37. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) Nature 391, 43-50[CrossRef][Medline] [Order article via Infotrieve]
  38. Morrow, J. S. (1989) Curr. Opin. Cell Biol. 1, 23-29[Medline] [Order article via Infotrieve]
  39. Bennett, V. (1990) Physiol. Rev. 70, 1029-1065[Free Full Text]
  40. Faucheu, C., Blanchet, A.-M., Collard-Dutilleul, V., Lalanne, J. L., and Diu-Hercend, A. (1996) Eur. J. Biochem. 236, 207-213[Abstract]
  41. Lazebnik, Y. A., Takahashi, A., Moir, R. D., Goldman, R. D., Poirier, G. G., Kaufmann, S. H., and Earnshaw, W. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9042-9046[Abstract]
  42. Orth, K., Chinnaiyan, A. M., Garg, M., Froelich, C. J., and Dixit, V. M. (1996) J. Biol. Chem. 271, 16443-16446[Abstract/Free Full Text]
  43. Takahashi, A., Alnemri, E. S., Lazebnik, Y. A., Fernandes-Alnemri, T., Litwack, G., Moir, R. D., Goldman, R. D., Poirier, G. G., Kaufmann, S. H., and Earnshaw, W. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8395-8400[Abstract/Free Full Text]
  44. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347[CrossRef][Medline] [Order article via Infotrieve]
  45. Song, Q., Lees-Miller, S. P., Kumar, S., Zhang, N., Chan, D. W., Smith, G. C. M., Jackson, S. P., Alnemri, E. S., Litwack, G., Khanna, K. K., and Lavin, M. F. (1996) EMBO J. 15, 3238-3246[Abstract]
  46. Sarin, A., Adams, D. H., and Henkart, P. A. (1993) J. Exp. Med. 178, 1693-1700[Abstract]
  47. Kumar, S., and Harvey, N. L. (1995) FEBS Lett. 375, 169-173[CrossRef][Medline] [Order article via Infotrieve]
  48. de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., Lemeur, M., Walztinger, C., Chambon, P., and de Murcia, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7303-7307[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.